---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043488"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2026-09-21T13:12:01+00:00"
generated_at: "2026-09-21T13:13:12.160407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InspireMD amends warrants, potential $11M proceeds tied to anticipated FDA approval of CGuard Prime 80 cm

## Summary
- Amended Series J (4.8M shares) and Series K (9.5M shares) warrants; exercise price for amended portion set at $0.7674.
- Potential gross proceeds up to $11M if exercised; no additional warrants issued.
- Termination date changed to May 15, 2028 or 20 trading days after FDA approval announcement; approval expected Q4 2026.
- Unchanged Series J half retains $1.3827 exercise price and SwitchGuard trigger.
- CGuard Prime 80 cm shows 100% acute success, zero MAEs at 30 days in 36-patient study; TCAR market doubles addressable opportunity.

## SEC filing metadata
- accession: 0001493152-26-043488
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2026-09-21T13:12:01+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315226043488/0001493152-26-043488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315226043488/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043488
- JSON: https://secwatch.observer/filing/0001493152-26-043488.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.